The 46% sales growth confirms strong commercial execution and market share gains, but the company acknowledges the comp was aided by depressed year-ago sales. Watch the Nov 13 full earnings call for margin data, cash flow, and capacity expansion updates — the real test is whether profitability scales with revenue.
Price Chart
Executive Summary
ImmuCell announced preliminary, unaudited Q3 2026 product sales of $8.0 million, a 46% increase YoY, driven by broad-based portfolio growth including Tri-Shield (+51%) and Dual-Force (+36%). The company also stated it will discontinue early sales reporting going forward, reverting to full quarterly financial disclosures. The prior quarter (Q1 2026) showed strong fundamentals with net income of $1.9M, 45% gross margins, and $3.4M free cash flow.
Key Financial Metrics
Key Facts
- Q3 2026 preliminary product sales of $8.0M, up 46% YoY from $5.5M in Q3 2025
- Domestic sales of $6.9M, up 29.2% YoY
- Nine-month 2026 total sales of $25.6M, up 27.8% YoY
- Tri-Shield grew 51%, Dual-Force grew 36%, functional feed line grew 37% in Q3
- Management will discontinue early sales reporting; next full financial report on Nov 13, 2026
- Prior Q1 2026: net income $1.9M, product sales $10.4M (+28.4% YoY), gross margin 45.0%
Financial Impact
Q3 sales of $8.0M represent a 46% YoY increase, with nine-month sales of $25.6M (+27.8%)
Risk Factors
- YoY growth rate will face tougher comps in Q4 as the prior-year backlog clears
- Discontinuation of early sales reporting reduces transparency between quarters
- Capacity expansion and manufacturing yield improvements remain execution risks
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032465 |
| Exhibit: ex_1024934.htm | 0001437749-26-032465 |
| Document: 0001437749-26-032465-index-headers.html | 0001437749-26-032465 |
| Document: 0001437749-26-032465-index.html | 0001437749-26-032465 |
| Document: 0001437749-26-032465.txt | 0001437749-26-032465 |
| 8-K Data (Synthetic) | 0001437749-26-032465 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $10.79 $10.45 | ▼ −3.15% | ▼ −2.00% | $10.24 (−5.10%) |
May 8, 2026 24w ago | 8-K | $8.45 $9.91 | ▲ +17.28% | ▲ +17.36% | $10.24 (+21.18%) |
Apr 8, 2026 28w ago | 8-K | $7.19 $7.54 | ▲ +4.87% | ▲ +1.68% | $10.24 (+42.42%) |
Apr 8, 2026 28w ago | Press Release | $7.19 $7.54 | ▲ +4.87% | ▲ +1.68% | $10.24 (+42.42%) |
Mar 4, 2026 33w ago | 8-K | $6.35 $6.63 | ▲ +4.41% | ▲ +6.65% | $10.24 (+61.26%) |
Mar 4, 2026 33w ago | Press Release | $6.35 $6.63 | ▲ +4.41% | ▲ +6.65% | $10.24 (+61.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers